Belite Bio, Inc - American Depositary Shares (BLTE)

Belite Bio Inc (NASDAQ: BLTE) stock falls after reporting Q3 net loss of $36.1M; analysts maintain Buy/Overweight rating, citing positive trial results.

BLTE stock results show that Belite Bio missed analyst estimates for earnings per share the second quarter of 2024.

BLTE stock results show that Belite Bio missed analyst estimates for earnings per share the first quarter of 2024.

Gainers Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares jumped 283.7% to $1.3007 after Harmony Biosciences entered into definitive agreement to acquire the company for total potential consideration of up to $200 million in cash.

The biopharmaceutical company announced a stock sale that's not great news to current investors.

The clinical-stage biotech company bounced back from a 52-week low late last week.

U.S. stocks traded mixed, with the Nasdaq Composite gaining around 60 points on Monday. Here are some big stocks recording gains in today’s session.

Gainers Benitec Biopharma Inc. (NASDAQ: BNTC) climbed 104% to $0.4050 after the company announced it received FDA clearance of the IND for BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy.

  Friday's session saw 32 companies set new 52-week lows.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Gainers Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) shares jumped 143% to $0.45 after the company announced it received agreement from the FDA on its proposed single confirmatory Phase 3 study of AR-301 and the clinical study design.

U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping over 100 points on Wednesday. The Dow traded down 0.82% to 32,773.27 while the NASDAQ fell 0.86% to 12,905.49. The S&P 500, also fell, dropping, 0.88% to 4,168.38.